2019 Non-Proliferative Diabetic Retinopathy (NPDR) Ongoing Clinical Trials Study- Companies, Countries, Drugs, Phases, Enrollment, Current Status and Markets

February 2019 | 47 pages | ID: 27E2EA5A200EN
VPAResearch

Abstracts

The ongoing clinical trial research report- “2019 Non-Proliferative Diabetic Retinopathy (NPDR) Ongoing Clinical Trials Study” analyzes the current scenario of all active Non-Proliferative Diabetic Retinopathy (NPDR) trials across the world. The report presents top level analysis of global Non-Proliferative Diabetic Retinopathy (NPDR) clinical trials across countries, companies and universities. It is designed to provide clear understanding into the Non-Proliferative Diabetic Retinopathy (NPDR) trials landscape to assist users for effective long term strategy formulation to beat competition.

The report covers a key snapshot of ongoing trial count, average enrollment per trial across countries.

It also segments the Non-Proliferative Diabetic Retinopathy (NPDR) clinical trials by-

• Region (Asia Pacific, Europe, Middle East Africa and Americas)
• Countries
• Trial Phase
• Current Trial Status (Recruiting, Active, Planned, Active but Completed Recruiting, Not Yet Recruiting etc)
• Type of the trial (Interventional, Observational)
• Sponsor Type (Companies, Universities, Government Bodies etc)
• Enrollment across types, sponsor types, geographies, current status and phases

The report also identifies the potential drug candidates under development for treatment of Non-Proliferative Diabetic Retinopathy (NPDR) on the basis of intervention type ongoing Non-Proliferative Diabetic Retinopathy (NPDR) trials.

The research work is prepared through extensive and continuous research on Non-Proliferative Diabetic Retinopathy (NPDR) trials from over 150 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

REPORT SCOPE AND COVERAGE:

• All major ongoing trials from 2010 to 2019 and planned trials are included in the report scope.
• Drug candidates currently being researched for administering Non-Proliferative Diabetic Retinopathy (NPDR) patients are identified
• The report includes panorama of ongoing Non-Proliferative Diabetic Retinopathy (NPDR) clinical trials across the globe
• Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
• Companies and universities focusing on Non-Proliferative Diabetic Retinopathy (NPDR) clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
• Average Enrollment number, insights into enrollment trends, company wise enrollment are included
• Both interventional and observational studies are analyzed
• News and latest developments for the past one year are presented in the report

Contents

1. TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2. EXECUTIVE SUMMARY

2.1 Non-Proliferative Diabetic Retinopathy (NPDR) Ongoing Clinical Trials Overview, 2019
2.2 Premium Insights into Ongoing Clinical Trials
  2.2.1 Ongoing Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials by Region
  2.2.2 Average Enrollment of Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials
  2.2.3 Companies participating in Ongoing Trials
  2.2.4 Drugs under Study for Non-Proliferative Diabetic Retinopathy (NPDR) Treatment, 2019

3. REGION WISE NON-PROLIFERATIVE DIABETIC RETINOPATHY (NPDR) CLINICAL TRIALS

3.1 Asia Pacific Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials by Country
3.2 Europe Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials by Country
3.3 North America Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials by Country
3.4 Middle East and Africa Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials by Country
3.5 South and Central America Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials by Country

4. NON-PROLIFERATIVE DIABETIC RETINOPATHY (NPDR) CLINICAL TRIAL TRENDS

4.1 Start Year wise Ongoing Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials
4.2 Phase wise Ongoing Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials
4.3 Trial Status wise Ongoing Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials
4.4 Trial Type wise Ongoing Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials

5. NON-PROLIFERATIVE DIABETIC RETINOPATHY (NPDR) AVERAGE ENROLLMENT TRENDS

5.1 Average Enrollment in Non-Proliferative Diabetic Retinopathy (NPDR) Trials by Year
5.2 Average Enrollment in Non-Proliferative Diabetic Retinopathy (NPDR) Trials by Phase
5.3 Average Enrollment in Non-Proliferative Diabetic Retinopathy (NPDR) Trials by Status
5.4 Average Enrollment in Non-Proliferative Diabetic Retinopathy (NPDR) Trials by Type of Trial

6. COMPANIES PARTICIPATING IN ONGOING NON-PROLIFERATIVE DIABETIC RETINOPATHY (NPDR) CLINICAL TRIALS

6.1 Ongoing Non-Proliferative Diabetic Retinopathy (NPDR) Trials by Sponsor Type
6.2 Non-Proliferative Diabetic Retinopathy (NPDR) Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7 TRIAL SNAPSHOTS- PHASE, TYPE, TITLE, LOCATION, START YEAR, COMPLETION YEAR, RECRUITMENT STATUS, ENROLLMENT, PARTICIPATING COUNTRIES, TRIAL LOCATIONS, COMPANY, DRUGS AND OTHER DETAILS

7.1 Ongoing Non-Proliferative Diabetic Retinopathy (NPDR) Trials- Phase
7.2 Ongoing Non-Proliferative Diabetic Retinopathy (NPDR) Trials- Phase
7.3 Ongoing Non-Proliferative Diabetic Retinopathy (NPDR) Trials- Phase
7.4 Ongoing Non-Proliferative Diabetic Retinopathy (NPDR) Trials- Phase

8. APPENDIX

8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List Of Figures

LIST OF FIGURES

Figure 1: Non-Proliferative Diabetic Retinopathy (NPDR) Ongoing Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific – Country wise Ongoing Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials and Enrolment
Figure 5: Europe – Country wise Ongoing Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials and Enrolment
Figure 6: Middle East Africa – Country wise Ongoing Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials and Enrolment
Figure 7: North America – Country wise Ongoing Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials and Enrolment
Figure 8: South and Central America – Country wise Ongoing Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials and Enrolment
Figure 9: Non-Proliferative Diabetic Retinopathy (NPDR) Ongoing Clinical Trials by Phase
Figure 10: Non-Proliferative Diabetic Retinopathy (NPDR) Ongoing Clinical Trials by Trial Status
Figure 11: Non-Proliferative Diabetic Retinopathy (NPDR) Ongoing Clinical Trials by Type
Figure 12: Non-Proliferative Diabetic Retinopathy (NPDR) Ongoing Clinical Trials by Sponsor Type
Figure 13: Non-Proliferative Diabetic Retinopathy (NPDR) Ongoing Clinical Trials by Leading Sponsors
Figure 14: Non-Proliferative Diabetic Retinopathy (NPDR) Average Enrollment by Phase
Figure 15: Non-Proliferative Diabetic Retinopathy (NPDR) Average Enrollment by Trial Status
Figure 16: Non-Proliferative Diabetic Retinopathy (NPDR) Average Enrollment by Type
Figure 17: Non-Proliferative Diabetic Retinopathy (NPDR)- Average Enrolment by Type of Sponsors
Figure 18: Non-Proliferative Diabetic Retinopathy (NPDR)- Enrolment by Leading Sponsors
Figure 19: VPAResearch- Research Methodology

List Of Tables

LIST OF TABLES

Table 1: Non-Proliferative Diabetic Retinopathy (NPDR) Ongoing Clinical Trials Snapshot- 2019
Table 2: Ongoing Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific – Country wise Ongoing Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials and Enrolment
Table 5: Europe – Country wise Ongoing Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials and Enrolment
Table 6: Middle East Africa – Country wise Ongoing Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials and Enrolment
Table 7: North America – Country wise Ongoing Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials and Enrolment
Table 8: South and Central America – Country wise Ongoing Non-Proliferative Diabetic Retinopathy (NPDR) Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Non-Proliferative Diabetic Retinopathy (NPDR) Average Enrollment by Phase
Table 15: Non-Proliferative Diabetic Retinopathy (NPDR) Average Enrollment by Trial Status
Table 16: Non-Proliferative Diabetic Retinopathy (NPDR) Average Enrollment by Type
Table 17: Non-Proliferative Diabetic Retinopathy (NPDR)- Average Enrolment by Type of Sponsors
Table 18: Non-Proliferative Diabetic Retinopathy (NPDR)- Enrolment by Leading Sponsors